Abstract
Digestive cryptosporidiosis (DC) can mimic GVHD after allogeneic haematopoietic stem cell transplantation (HSCT), thus requiring a reduction of immunosuppressive drugs and a specific therapy, whereas GVHD requires an intensification of immunosuppression. We systematically searched for cryptosporidiosis by light microscopy, immunochromatography and PCR in HSCT recipients who presented with at least one episode of diarrhoea. Of 115 consecutive patients allografted between July 2006 and November 2008, we analysed stools in 52 of 56 patients meeting these criteria. We identified Cryptosporidium parvum in 5 of the 52 patients (9.6%) at a median of 503 days (range 20–790) after HSCT. In those five patients, the median CD4+ cell and B lymphocyte counts were 60/mm3 (0–234) and 0/mm3 (0–96), respectively. Two patients died of invasive fungal infections. In the other three patients, diarrhoea disappeared after a median of 5 weeks following onset of bitherapy with azithromycine and nitazoxanide; they were still alive 433, 380 and 1179 days after the DC diagnosis. DC is probably under diagnosed after HSCT because it is difficult to detect during the asymptomatic phase. Early bitherapy and reduction of immunosuppression seem efficacious. In our series, DC has a seasonal pattern and is promoted by profound T lymphopenia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W . The infectivity of Cryptosporidium parvum in healthy volunteers. N Engl J Med 1995; 332: 855–859.
Blanshard C, Jackson AM, Shanson DC, Francis N, Gazzard BG . Cryptosporidiosis in HIV-seropositive patients. Q J Med 1992; 85: 813–823.
Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158: 977–983.
Burgner D, Pikos N, Eagles G, McCarthy A, Stevens M . Epidemiology of Cryptosporidium parvum in symptomatic paediatric oncology patients. J Paediatr Child Health 1999; 35: 300–302.
Gentile G, Venditti M, Micozzi A, Caprioli A, Donelli G, Tirindelli C et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis 1991; 13: 842–846.
Faraci M, Cappelli B, Morreale G, Lanino E, Moroni C, Bandettini R et al. Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant? Pediatr Transplant 2007; 11: 113–116.
Manivel C, Filipovich A, Snover DC . Cryptosporidiosis as a cause of diarrhea following bone marrow transplantation. Dis Colon Rectum 1985; 28: 741–742.
Muller CI, Zeiser R, Grullich C, Finke J, Bertz H, Schmitt-Graff A et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. Transplantation 2004; 77: 1478–1479.
Rio B, Le Tourneau A, Sobahni I, Audouin J, Bouvet A, Diebold J et al. Cryptosporidiosis in grafting of allogeneic bone marrow]. Presse Med 1986; 15: 1414–1416.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
de la Cruz-Vicente F, Cerezuela Martinez P, Gil-Esparraga E, Martin Aguilera C, Aguilar Guisado M, Parody Ruiz-Berdejo R et al. Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients. Transplant Proc 2008; 40: 3102–3103.
Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H . Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1–207, quiz CE1-4.
Dalle F, Roz P, Dautin G, Di-Palma M, Kohli E, Sire-Bidault C et al. Molecular characterization of isolates of waterborne Cryptosporidium spp. collected during an outbreak of gastroenteritis in South Burgundy, France. J Clin Microbiol 2003; 41: 2690–2693.
Weitzel T, Dittrich S, Mohl I, Adusu E, Jelinek T . Evaluation of seven commercial antigen detection tests for Giardia and Cryptosporidium in stool samples. Clin Microbiol Infect 2006; 12: 656–659.
McLauchlin J, Amar CF, Pedraza-Diaz S, Mieli-Vergani G, Hadzic N, Davies EG . Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003; 22: 329–335.
Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W, Dupont HL . Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C parvum serum immunoglobulin G. Am J Trop Med Hyg 1999; 60: 157–164.
Stiehm ER, Chin TW, Haas A, Peerless AG . Infectious complications of the primary immunodeficiencies. Clin Immunol Immunopathol 1986; 40: 69–86.
Gait R, Soutar RH, Hanson M, Fraser C, Chalmers R . Outbreak of cryptosporidiosis among veterinary students. Vet Rec 2008; 162: 843–845.
Valderrama AL, Hlavsa MC, Cronquist A, Cosgrove S, Johnston SP, Roberts JM et al. Multiple risk factors associated with a large statewide increase in cryptosporidiosis. Epidemiol Infect 2009; 137: 1781–1788.
Semenza JC, Nichols G . Cryptosporidiosis surveillance and water-borne outbreaks in Europe. Euro Surveill 2007; 12: E13–E14.
Smith HV, Corcoran GD . New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004; 17: 557–564.
Anderson VR, Curran MP . Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67: 1947–1967.
Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002; 360: 1375–1380.
Acknowledgements
We thank Frances Sheppard of the Clinical Investigation Centre of Besançon for correcting and improving the English of this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Legrand, F., Grenouillet, F., Larosa, F. et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant 46, 858–862 (2011). https://doi.org/10.1038/bmt.2010.200
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.200
Keywords
This article is cited by
-
An update on Cryptosporidium biology and therapeutic avenues
Journal of Parasitic Diseases (2022)
-
Molecular Basis of P131 Cryptosporidial-IMPDH Selectivity—A Structural, Dynamical and Mechanistic Stance
Cell Biochemistry and Biophysics (2021)
-
Prevalence of Cryptosporidium, Blastocystis, and other opportunistic infections in patients with primary and acquired immunodeficiency
Parasitology Research (2018)
-
Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward
Current Tropical Medicine Reports (2015)